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ABSTRACT 113 
 114 
Background: We conducted a large international study to estimate fractions of head and neck 115 
cancers (HNCs) attributable to HPV (HPV-AFs) using six HPV-related biomarkers of viral 116 
detection, transcription, and cellular transformation. 117 
Methods: Formalin-fixed, paraffin-embedded cancer tissues of the oral cavity (OC), pharynx and 118 
larynx were collected from pathology archives in 29 countries. All samples were subject to 119 
histopathological evaluation, DNA quality control, and HPV-DNA detection. Samples containing 120 
HPV-DNA were further subject to HPV E6*I mRNA detection and to p16INK4a, pRb, p53, and 121 
Cyclin D1 immunohistochemistry. Final estimates of HPV-AFs were based on HPV-DNA, HPV 122 
E6*I mRNA, and/or p16INK4a results. 123 
Results: A total of 3,680 samples yielded valid results: 1,374 pharyngeal, 1,264 OC, and 1,042 124 
laryngeal cancers. HPV-AF estimates based on positivity for HPV-DNA, and for either HPV E6*I 125 
mRNA or p16INK4a were 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, OC, and larynx, 126 
respectively, and 18.5%, 3.0%, and 1.5% when requiring simultaneous positivity for all three 127 
markers. HPV16 was largely the most common type. Estimates of HPV-AF in the oropharynx 128 
were highest in South America, Central and Eastern Europe and Northern Europe, and lowest in 129 
Southern Europe. Women showed higher HPV-AFs than men for cancers of the oropharynx in 130 
Europe and for the larynx in South America. 131 
Conclusions: HPV contribution to HNCs is substantial but highly heterogeneous by cancer site, 132 
region, and gender. This study, the largest exploring HPV attribution in HNCs, confirms the 133 
important role of HPVs in oropharyngeal cancer and drastically downplays the previously 134 
reported involvement of HPVs in the other HNCs. 135 
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INTRODUCTION 137 
 138 
Strong evidence has accumulated in the last 15 years showing that certain human 139 
papillomaviruses (HPVs) are etiologically involved in a subset of head and neck cancers 140 
(HNCs)1. While virtually all cervical cancers are considered HPV driven2 the quantitative 141 
assessment of the etiological involvement of HPVs in HNCs is challenged by its multifactorial 142 
etiology largely attributed to tobacco and alcohol use3-5. Consequently, the unequivocal fraction 143 
of HPV-DNA-positive HNCs for which HPV infection is indeed the truly triggering carcinogenic 144 
event is unknown, and its estimation remains a challenge6. Further, the presence of HPV-DNA in 145 
HNCs is not sufficient to prove viral causation as it might just reflect a transient infection 146 
unrelated to the carcinogenic process7,8. It is thus crucial to explore the individual and combined 147 
expression patterns of other markers associated with HPV-induced carcinogenesis to assess the 148 
biological and oncogenic activities of HPVs identified in these cancers.  149 
To that end we conducted a large international study in HNCs to assess levels of six 150 
markers associated with HPV carcinogenesis using a strict single protocol to standardize the 151 
entire process that spans from sample selection and processing to pathology review and testing. 152 
The ultimate goal of the study was to generate robust estimates of the HPV attributable fractions 153 
(AFs) in HNCs by anatomical site, gender, and geography. 154 
  155 
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METHODS 156 
 157 
We carried out an international, cross-sectional study to assess the prevalence of viral 158 
DNA and other markers of HPV-related carcinogenesis in formalin-fixed paraffin-embedded 159 
(FFPE) samples of HNCs. Protocols were approved by the ethics committee of the Catalan 160 
Institute of Oncology (Comitè Ètic d'Investigació Clínica de l'Hospital Universitari de Bellvitge, 161 
L’Hospitalet de Llobregat, Spain), which required no informed consent to use archived tumor 162 
samples.  163 
 164 
Selection of HNC cases and control tissue 165 
HNC samples were selected from an international network of pathology departments 166 
identified in 44 centers in 29 countries in Europe, Africa, Asia, and America. Participating centers 167 
were requested to provide samples using a common protocol for sample selection, retrieval, 168 
processing, and shipping to ICO. Selected cancer cases had to fulfill pre-established inclusion 169 
criteria: to be diagnosed with primary invasive cancer of the oral cavity (OC), pharynx or larynx 170 
under specific codes of the International Classification of Diseases version 10 (ICD-10); to have 171 
complete data on year of diagnosis and site of the tumor; and to be selected in a consecutive or 172 
random manner from 1990 onwards. Centers were asked to contribute if possible a minimum of 173 
50 samples per major anatomic HNC site. In order to assess potential carry over contamination 174 
at the local level we additionally requested tissue samples of patients with non-HPV related 175 
diagnoses processed in the same laboratory and close to the cases’ diagnosis time. Cancers of 176 
the salivary glands, nasopharynx and external lip were initially not requested since they are a 177 
priori not considered to be related to HPVs. Nevertheless, we included a series of 178 
nasopharyngeal cancers from Europe (n=37), America (n=8), Africa (n=35) and Asia (n=21). 179 
HPV in head and neck cancer    9 
Based on previously published site-specific estimates of HPV-DNA prevalence9, optimal 180 
sample size was set at around 1,000 cases per major cancer site in order to obtain HPV-DNA 181 
prevalence estimates with a ±2.5% precision. 182 
 183 
FFPE blocks processing and histopathological evaluation 184 
FFPE blocks were re-embedded at ICO whenever necessary. At least four paraffin 185 
sections were obtained for each block. First and last sections were used for histopathological 186 
evaluation and the in-between ones for HPV testing (sandwich method). Additional slides were 187 
obtained to assess expression of cellular proteins by immunohistochemistry (IHC). FFPE blocks 188 
were processed under strict pre/post PCR physical separation, and blank paraffin blocks were 189 
systematically tested in parallel to serve as sentinels for contamination as previously 190 
published10. Pathology review was performed blind with respect to the original local diagnosis 191 
and followed a pre-established algorithm for diagnostic consensus involving four pathologists. 192 
First, all cases were reviewed by a trained pathologist at ICO. Cases regarded as difficult to 193 
classify (n=668) were further reviewed by two senior expert pathologists also at ICO. Finally, 194 
cases having still an unclear histopathological diagnosis after the second review (n=67) as well 195 
as a random sample of approximately 10% of the first 2000 cases (n=182) were blindly re-196 
evaluated by an external expert pathologist for a final evaluation. If there were discrepancies 197 
with the local collaborating center, the expert diagnosis prevailed. Pathological classification was 198 
based on the WHO pathological criteria for HNCs11. 199 
 200 
 201 
HPV-DNA detection and genotyping  202 
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The detailed methods used for HPV-DNA detection and genotyping have been reported 203 
elsewhere in a similar study on cervical cancer specimens10. Briefly, we used SPF-10 PCR and 204 
a DNA enzyme immunoassay (DEIA) to test for the presence of HPV-DNA. Virus genotyping 205 
was performed using reverse hybridization line probe assay (LiPA25_v1) on all samples testing 206 
positive for viral DNA, targeting 25 HPV types with different oncogenic potential. Specimens 207 
testing positive for HPV-DNA by DEIA but that could not be typed by LiPA25 were further 208 
analyzed by direct Sanger sequencing of PCR products12. HPV-DNA positive cases that could 209 
not be sequenced were labeled as "HPV undetermined". DNA quality was evaluated in all HPV-210 
DNA negative samples by testing for the human tubulin gene13. All DEIA and LiPA25_v1 assays 211 
were performed at ICO. These assays were quality controlled and validated against an external 212 
HPV reference lab (DDL Diagnostic Laboratory, Rijswijk, The Netherlands) by cross-testing of 213 
387 anogenital and head and cancer samples with overall percentage agreements and Kappa 214 
values of 92.8% (95% CI 89.7-95.1) and 0.78 (95% CI, 0.71-0.86), respectively, for DEIA, and 215 
91.2% (95% CI 87.9-93.8) and 0.74 (95% CI 0.66-0.82), respectively, for HPV genotyping.  216 
 217 
HPV E6*I mRNA detection 218 
All HPV-DNA positive samples underwent RNA extraction and E6*I mRNA detection at 219 
DKFZ, Heidelberg, Germany, as developed by Halec and colleagues14. Briefly, the assays target 220 
a total of 20 HPV types. For each sample, type-specific E6*I mRNA RT-PCR was performed for 221 
all available HPV types detected at the DNA level, and additionally for HPV16. A random 222 
selection (0.6%) of HPV-DNA negative cases was tested for HPV16 E6*I mRNA. Detection of 223 
housekeeping gene ubiquitin C mRNA was used for RNA quality control in all tested cases. 224 
 225 
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Immunohistochemistry 226 
Protein expression patterns were evaluated for p16INK4a, pRb, p53, and Cyclin D1 in all 227 
HPV-DNA positive samples, and in a random selection of HPV-DNA negative cases in a ratio of 228 
1:1, corresponding approximately to 12% of the negative cases. Stainings were all performed at 229 
Hospital General de L’Hospitalet, L’Hospitalet de Llobregat, Spain, under the manufacturer’s 230 
standards: Roche mtm Laboratories AG (Heidelberg) for p16INK4a, Vision Biosystems Novocastra 231 
(Newcastle) for pRb, and Dako (Denmark) for p53 and Cyclin D1. We used the predefined 232 
algorithm developed by Halec and colleagues15 to determine the cut-off values for over- versus 233 
under-expression of each protein. The expected pattern for HPV-driven cases was over-234 
expression of p16INK4a and under-expression of the other three markers. 235 
 236 
Statistical analyses 237 
Cases testing negative for both viral and human DNA were excluded from the analyses. 238 
HPV-DNA prevalence was calculated as the fraction of HPV-DNA positive cases by SPF-10 239 
PCR/DEIA among all samples providing a valid HPV DNA result.  240 
In line with work from several authors15-17, we established that in order to explore 241 
algorithms to classify a HNC as HPV-driven we needed to consider markers of HPV infection 242 
(HPV-DNA detection), markers of transcriptional activity of HPV oncogenes (HPV E6*I mRNA), 243 
and surrogate markers of HPV-related cellular transformation (p16INK4a, pRb, p53 and Cyclin 244 
D1). We used HPV-DNA and HPV-mRNA positivity as the gold standard to explore the 245 
additional value of the other four surrogate markers of cellular transformation by using statistical 246 
indicators such as sensitivity, specificity, odds ratios and area under the ROC curves. As shown 247 
in Supplementary Table 1, p16INK4a expression was the marker that showed the most consistent 248 
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association with the gold standard across anatomical sites. None of the other markers or 249 
combination of markers showed a statistically significant higher area under the ROC curve. 250 
Thus, we concluded that using p16INK4a and/or HPV-mRNA in addition to HPV-DNA yielded the 251 
most accurate approximation to judge HPV carcinogenicity in HNCs. Accordingly, we report 252 
ranges of estimated HPV-AFs by using different combinations of positivity by these three 253 
markers (Figure 2). HPV-AFs are expressed as the percentage of positive samples for the 254 
marker or combination of markers among all samples validly tested for the corresponding marker 255 
or markers, and 95% confidence interval (CI) around point estimates are presented. 256 
We performed sensitivity analyses for p16INK4a positivity according to three different cutoff 257 
points of percentage of stained cells: >25%, >50%, and >75% (Supplementary Table 2). Since 258 
there were no statistically significant differences in the estimates across the three cutoff values, 259 
and for consistency sake, we used the >25% cutoff as used by Halec et al.15. For the 260 
geographical analyses, countries were grouped into world subregions according to the Globocan 261 
classification18. All statistical tests were two-sided and statistical significance was set at a P 262 
value of less than .05. All analyses were performed with STATA version 10.1 (StataCorp. 263 
2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP)  264 
 265 
 266 
RESULTS 267 
 268 
Figure 1 depicts the disposition of HNC samples collected, processed and finally tested. 269 
The laboratory at ICO received a total of 4,533 samples of which 4,022 were tested for HPV-270 
DNA. A total of 3,680 HNC samples yielded a valid DNA result and were included in the final 271 
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analysis: 1,264 from the OC, 1,374 from the pharynx, and 1,042 from the larynx. As compared to 272 
other regions, Africa and Asia proportionally contributed more invalid samples (i.e., those testing 273 
both HPV-DNA and tubulin negative) than the other regions: 19.5% and 21.1%, respectively, 274 
versus 8.5% in Central-South America, and 5% in Europe. Also, samples collected from older 275 
periods (1990-2004) were more frequently invalid than those collected from more recent periods 276 
(2005-2012): 12.6% versus 6.9%, respectively. In contrast, no differences in the percentage of 277 
excluded samples were observed by age or gender. Figure 1 also shows the number of HPV-278 
DNA positive samples that were finally tested for the five additional markers and yielded a valid 279 
result.  280 
Table 1 summarizes the characteristics of HNC patients included in the analysis. Most 281 
samples were recruited from centers in Europe (55.7%) and Central-South America (28.2%). 282 
Patients were mostly men (76.2%) with a mean age at diagnosis of 61 years. Patients were 283 
mainly diagnosed within the 2000-2009 decade (65.3%). The most frequent histological 284 
diagnosis was squamous cell carcinoma (99.1%) of conventional keratinizing type (65.3%). 285 
Table 2 shows HPV-DNA prevalence estimates and HPV type-specific distributions by 286 
HNC site. Highest HPV prevalence was observed in the oropharynx (25.0%), followed by 287 
pharynx unspecified (21.4%), nasopharynx (8.9%), OC (7.4%), larynx (5.9%), and hypopharynx 288 
(3.9%). Supplementary Table 3 presents detailed HPV-DNA data for each anatomic sub-site. 289 
Among sub-sites with at least 45 tested cases, cancer of the tonsils showed the highest HPV-290 
DNA prevalence (47%), followed by base of the tongue (18.5%), and oropharynx unspecified 291 
(18.2%). HPV16 was by far the most frequently detected genotype among HPV-DNA positive 292 
cases (76.2%), in particular in the oropharynx (83.2%). Table 2 also presents the results of the 293 
HPV-driven expected patterns of the other markers. Among HPV-DNA positive cases, under-294 
expression of p53 and HPV E6*I mRNA detection showed the highest prevalence estimates for 295 
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the three major cancer sites. Among HPV-DNA negative cancer samples, p16INK4a over-296 
expression was 13.2%, 10.5%, and 6.6% for OC, oropharynx and larynx, respectively (data not 297 
shown). Corresponding values for under-expression of pRb were 33.7%, 25.1%, and 24.0%; for 298 
p53: 59.3%, 48.8%, and 50.6%; and for Cyclin D1: 15.7%, 18.0%, and 23.7%. None of the 299 
randomly selected oropharyngeal HPV-DNA negative samples (n=20) tested positive for HPV 300 
E6*I mRNA (data not shown).  301 
Figure 2 presents estimated HPV-AFs using HPV-DNA, HPV E6*I mRNA detection and 302 
over-expression of p16INK4a. Ranges of AFs when considering HPV-DNA plus E6*I mRNA and/or 303 
p16INK4a were: 18.5 to 22.4% for the oropharynx, 3.0 to 4.4% for the OC, and 1.5 to 3.5% for the 304 
larynx. Corresponding values when considering positivity by both HPV-DNA and E6*I mRNA 305 
were 21.8%, 3.9%, and 3.1%, respectively. Full results by cancer subsite are provided in 306 
Supplementary Table 3. We observed that within both the oral cavity and the larynx, those 307 
subsites that were more proximal to the oropharynx showed higher HPV-AFs than those that 308 
were more distal to the oropharynx. Thus, HPV-AFs in combined oral cavity subsites that were 309 
proximal to the oropharynx ranged (when considering HPV-DNA plus E6*I mRNA and/or 310 
p16INK4a) from 4.9% to 6.7%, as opposed to 1.4-2.3% in subsites that were distal to the 311 
oropharynx (p<0.001 for both comparisons). Corresponding values in the larynx were 4.2-4.2% 312 
versus 1.4-3.4% in combined subsites that were proximal versus distal to the oropharynx, but 313 
these differences were not statistically significant.  314 
Table 3 shows prevalence estimates of the key HPV-related markers as well as the final 315 
HPV-AF estimates by selected patients’ characteristics. Excluding strata with low numbers, 316 
HPV-AFs were highest in Central-South America, followed generally by Europe. Globally, 317 
women showed higher HPV-AFs than men for cancers of the oropharynx and larynx. For 318 
oropharyngeal cancer, HPV-AFs were higher in women as compared with men in all European 319 
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subregions -Central-Eastern Europe (61.5% versus 45.5%, p=0.09), Southern-Europe (22.6% 320 
versus 8.4%, p=.002), Western Europe (38.9% versus 13%, p=.02)-, except Northern Europe 321 
(50% versus 50%). HPV-AFs were also higher in women as compared with men for cancers of 322 
the larynx in South America (23.1% versus 4.2%, p<.0001), as well as in Southern Europe (5.9% 323 
versus 0.5%, p=.03). In contrast, in the oral cavity we found higher HPV-AFs in men than in 324 
women, but only in Northern Europe (10.9% versus 0%, p=.01). We did not identify a clear 325 
pattern of gender differences by calendar period within regions showing gender differences in 326 
HPV-AF estimates (data not shown). An inverse trend was observed between HPV-AFs and 327 
increasing age at diagnosis for each major site. Concerning time trends, HPV-AFs for the 328 
oropharynx clearly increased over time: 7.2%, 10.1%, 18.7%, 26.1% and 32.7% for calendar 329 
periods 1990-1994, 1995-1999, 2000-2004, 2005-2009, and 2010-2012, respectively. In 330 
contrast, no trends were observed for the other two major HNC sites. 331 
HPV-AFs showed a marked geographic heterogeneity that was particularly evident for 332 
oropharyngeal cancer (Figure 3). For the oropharynx, AF estimates when considering HPV-DNA 333 
plus E6*I mRNA and/or p16INK4a were highest in South America (48.4%-53.6%), Central-Eastern 334 
Europe (44.9%-50%), and Northern Europe (25%-50%), and lowest in Southern Europe (7.6%-335 
9.4%). For the oral cavity corresponding estimates were highest in South America (5.5%-7.3%), 336 
Northern Europe (4.2%-6.8%), and Central America (4.3%); and for the larynx, in South America 337 
(3.8%-6.5%), Central America (1.4%-5.6%), and Northern Europe (4.2%). Full results by 338 
geographic area are provided in Supplementary Table 4. Since the study was not powered to 339 
calculate precise country-specific estimates, AFs by country are not provided.  340 
 341 
DISCUSSION 342 
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 343 
To our knowledge this study is the most focused and robust attempt to date to estimate the 344 
fraction of HNCs that might be driven by HPV infection. It is now well recognized that the mere 345 
detection of HPV-DNA is not sufficient to establish causality in HNCs. We have thus 346 
systematically assessed five additional markers related to HPV biological activity: HPV E6*I 347 
mRNA expression, and p16, pRb, p53, and Cyclin D1 protein detection. Each of these markers 348 
has advantages and limitations5,19. However, one of the key indicators of HPV-related 349 
carcinogenicity is HPV E6*I mRNA expression, a marker of transcriptional activity of HPV 350 
oncogenes14,20. Consequently, we have used both HPV-DNA and mRNA detection as the gold 351 
standard to assess the potential value of adding other surrogate markers of HPV-induced 352 
cellular transformation. As shown in Figure 2, using either or both E6*I mRNA or p16INK4a in 353 
addition to HPV-DNA yielded comparable AFs that were in the range of 18.5 to 22.4% for 354 
oropharyngeal cancer, 3.0 to 4.4% for OC cancer, and 1.5 to 3.5% for laryngeal cancer. The 355 
percentage point differences between the two methods ranged from 1.4 to 3.9, and they were 356 
basically due to lack of expression of p16INK4a in certain HPV-DNA+/mRNA+ samples. The loss 357 
of p16INK4a in these cancers might be a result of increasing genetic and epigenetic chromosomal 358 
instability induced by HPV oncoproteins.20 359 
The first observation when assessing these HPV-AFs is the marked heterogeneity across 360 
anatomic sites, being highest in the oropharynx, substantially lower in the OC, and even lower in 361 
the larynx. The probability of an HPV-driven OC cancer was between 4 and 7 times lower than 362 
that of oropharyngeal cancer; and that of an HPV-driven laryngeal cancer between 5 and 15 363 
times lower than that of oropharyngeal cancer. Even within a major site such as the oropharynx, 364 
AF estimates ranged from 4.0% in the posterior wall to 45.2% in the tonsil (Supplementary Table 365 
3). Being an oropharyngeal subsite, we found an unexpected low HPV-AF for cancers of the 366 
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base of tongue (between 8.7% and 17.4%), but also realized that most of these cases (68/92, 367 
74%) were from Spain, a country known to have low HPV-AFs for HNCs even for the oropharynx 368 
(6.7% to 8.6%). It is interesting to note that HPV-AFs for subsites within the oral cavity that were 369 
more proximal to the oropharynx were higher than those that were more distal from the 370 
oropharynx. Even though the same was observed for subsites in the larynx these differences did 371 
not reach statistical significance. This gradient of lower HPV involvement in more distant 372 
subsites from the oropharynx suggests either misclassification of anatomic subsite or a true 373 
biological gradient of HPV involvement.  374 
It is important to note that our estimates of HPV-AFs are substantially lower than those 375 
published in the most recent meta-analysis of HPV in HNCs8: 39.8%, 16.3%, and 8.6% in the 376 
oropharynx, OC and larynx, respectively, when using HPV-mRNA and HPV-DNA positivity. The 377 
discrepancy may be due to the very low number of studies reporting on more than one marker, 378 
to differences in the geographic origin of the samples, as well as to the high heterogeneity in the 379 
laboratory procedures and assays used across studies. In contrast, our AF estimates for the 380 
oropharynx (18.5-22.4%) are relatively consistent with another review reporting a population 381 
HPV-AF of 25.6%21. 382 
As shown in Table 3 we also found important heterogeneity of HPV-AF estimates by 383 
geographical region, gender and age at diagnosis. Estimates ranged from 0% in Africa or Asia to 384 
6.6% in Central-South America for OC; from 18.5% in Asia to 40.5% in Central-South America 385 
for the oropharynx; and from 0% in Asia to 6.1% in Central-South America for the larynx. Even 386 
within European sub-regions, wide variations were observed for each cancer site 387 
(Supplementary Table 4). Even though these estimates may seem low for some regions it is 388 
difficult to make fair comparisons as there are no large studies using several markers of HPV 389 
involvement. However, if we use just HPV DNA detection our estimates are substantially lower 390 
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that those recently reported for instance in a population-based study in the US in which HPV-391 
DNA was detected in 70.1% of oropharyngeal, 32.0% of oral cavity, and 20.9% of laryngeal 392 
cancers22. Concerning gender, HPV-AFs estimates were substantially higher in women than in 393 
men, but these differences were only statistically significant in Europe (in all European sub-394 
regions except Northern Europe) for oropharyngeal cancer, and in South America for laryngeal 395 
cancer. Finally, we also found that the magnitude of AFs decreased with increasing age for each 396 
of the three major HNC sites. 397 
We speculate that globally, this large heterogeneity in HPV-AFs most likely reflects distinct 398 
trends in temporal, geographical and sociodemographic shifts in population exposure to both 399 
tobacco smoking and oral HPV infection, leading to a rapidly evolving epidemiology of HPV-400 
positive HNCs. Indeed, pronounced increasing trends in the incidence of HPV-positive HNCs 401 
have been consistently observed in the last decade, in particular for HPV-positive oropharyngeal 402 
cancers in young men in Northern Europe and North America5,23-26. It could be hypothesized that 403 
the potential carcinogenic effects of highly prevalent tobacco smoking in the oropharynx 404 
between the 60’s and early 80’s dominated over those induced by low prevalent oral HPV 405 
infections. Since the 80’s, at least in certain populations, the high smoking/HPV prevalence 406 
ratios progressively diminished, and while population exposure to tobacco smoking decreased, 407 
exposure rates to oral HPV simultaneously increased due to increasing use of oral sex practices. 408 
Thus, the current burden of HPV-driven HNCs in a given population may substantially depend 409 
on the prevalence and subsequent trends of these exposures starting 15 to 25 years before. 410 
Given that our samples were gathered from diverse populations, age groups and time periods, 411 
our estimates might be substantially underestimating the current true burden of HPV-driven 412 
HNCs in some geographical areas of the world.  413 
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In contrast to previous reports, an important new finding of our data is the small HPV-AFs 414 
that we found for cancers of the oral cavity (<4.4%) and larynx (<3.5%). These small HPV-AFs 415 
could well be within the false-positive rate of triple-positivity by HPV-DNA, mRNA, and p16. We 416 
could also speculate that for these two cancers HPV might be a bystander infection taking 417 
advantage of a tumor that was caused by other means. Therefore, this study cannot rule out a 418 
potential effect of false-positivity, reverse-causation, misclassification of anatomical subsite, or 419 
some other artifact of our cross-sectional design, and thus conclude that HPV involvement in 420 
oral and laryngeal carcinogenesis is probably anecdotal. This could be also the case for the 421 
oropharynx, but since the HPV-AFs for this site are higher, the overall impact would be much 422 
lower than that in the oral cavity or the larynx.  423 
Despite its strong design and large sample size, our study is not free of limitations. The 424 
main one is that while we tested all samples for the presence of HPV-DNA, the five additional 425 
markers were assessed in HPV-DNA positive samples and only in a small fraction of HPV-DNA 426 
negative cases. We therefore cannot completely rule out that we were missing some truly HPV-427 
driven cases. However, our control testing for HPV16 mRNA among HPV-DNA negative 428 
samples was systematically negative. The effect of this potential misclassification would be 429 
towards underestimating the true role of HPV in head and neck carcinogenesis. Lack of 430 
representativeness of included samples from a given country or geographic region is also a 431 
potential limitation. The small number of samples included from North America and Africa, for 432 
instance, limits the validity of our results for these regions. It is clear also that the study is not 433 
population based, and as such, one cannot exclude some degree of referral or selection bias 434 
(i.e., centers could serve a biased population in a manner that might be associated with HPV-435 
AFs). The fact that we required participating centers to provide unselected, consecutive HNC 436 
samples reduced to a certain degree the potential for selection bias within each center, but not 437 
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that in the country as a whole. Related to this, it is important to emphasize that the use of overall 438 
(i.e., worldwide) HPV-AF should not be used nor applied to any one geographic region for the 439 
purpose of establishing health policy (for example, cost effectiveness analysis of vaccination). 440 
Region- and cancer site-specific data should be used instead. There has been a problem in 441 
misuse of prior data, and having this incorrect use of HPV-AFs may have an erroneous impact. 442 
In conclusion, this study presents robust evidence that the fraction of oropharyngeal 443 
cancers that are likely driven by HPV infection, mainly HPV16, is substantial (between 18.5% 444 
and 22.4%) but highly heterogeneous with anatomic subsite, geography and gender. In contrast, 445 
the etiological fraction of HPV in cancers of the OC and larynx is substantially lower than 446 
previously reported (<4.5%) and also less heterogeneous. Given the rapidly changing 447 
epidemiology of HPV-positive HNCs, our estimates might still be underestimating the true impact 448 
of HPV in oropharyngeal cancers, and it is likely that in the near future these AFs become even 449 
higher. Estimation of the real and evolving contribution of HPV to HNCs is key to forecast the 450 
future burden of these cancers as well as to inform on the global potential preventative impact of 451 
prophylactic HPV vaccination. 452 
   453 
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Table 1. Descriptive characteristics of head and neck cancer cases included in the study  574 
 575 
  
Oral cavity 
 
Nasopharynx 
 
Oropharynx 
 
Hypopharynx 
 
Pharynx 
unspecified 
 
Larynx 
  n=1,264  n=101  n=1,090  n=127  n=56  n=1,042 
  n %   n %   n %   n %   n %   n % 
Geographical origin                                   
Europe 587 46.4 
 
37 36.6 
 
810 74.3 
 
83 65.4 
 
28 50.0 
 
505 48.5 
North America 32 2.5 
 
0 0.0 
 
13 1.2 
 
5 3.9 
 
0 0.0 
 
34 3.3 
Central-South America 488 38.6 
 
8 7.9 
 
158 14.5 
 
12 9.4 
 
12 21.4 
 
359 34.5 
Africa 58 4.6 
 
35 34.7 
 
6 0.6 
 
26 20.5 
 
4 7.1 
 
73 7.0 
Asia 99 7.8 
 
21 20.8 
 
103 9.4 
 
1 0.8 
 
12 21.4 
 
71 6.8 
Gender  
                 Male 781 62.4 
 
75 74.3 
 
884 83.2 
 
99 78.6 
 
37 74.0 
 
929 89.5 
Female 471 37.6 
 
26 25.7 
 
178 16.8 
 
27 21.4 
 
13 26.0 
 
109 10.5 
Missing 12 - 
 
0 - 
 
28 - 
 
1 - 
 
6 - 
 
4 - 
Year of diagnosis 
 
     
1990-1994 35 2.8  5 5.0  83 7.6  1 0.8  1 1.8  18 1.7 
1995-1999 66 5.2  36 35.6  129 11.8  3 2.4  4 7.1  26 2.5 
2000-2004 152 12.0  20 19.8  226 20.7  9 7.1  12 21.4  156 15.0 
2005-2009 693 54.8  36 35.6  455 41.7  69 54.3  32 57.1  542 52.0 
2010-2012 318 25.2  4 4.0  197 18.1  45 35.4  7 12.5  300 28.8 
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 Range 1990-2012 
 
    1990-2011 1990-2012 
 
   1993-2012    1990-2011 1990-2012 
Age at diagnosis                                   
≤53 336 28.5 
 
36 37.5 
 
273 25.9 
 
33 26.2 
 
9 16.4 
 
210 20.9 
54-61 256 21.7 
 
21 21.9 
 
293 27.7 
 
31 24.6 
 
17 30.9 
 
293 29.2 
62-70 273 23.2 
 
16 16.7 
 
285 27.0 
 
40 31.7 
 
15 27.3 
 
287 28.6 
≥71 313 26.6 
 
23 24.0 
 
205 19.4 
 
22 17.5 
 
14 25.5 
 
214 21.3 
Missing 86 - 
 
5 - 
 
34 - 
 
1 - 
 
1 - 
 
38 - 
Mean age at diagnosis (SD) 61.4 (14.0) 
 
56.6 (16.4) 
 
61.0 (11.2) 
 
58.1 (16.0) 
 
62.3 (11.8) 
 
61.8 (10.9) 
Age range 17-98  16-93   20-92   17-91  26-87   18-89 
Histological diagnosis                                   
Squamous Cell Carcinoma 1,257 99.4 
 
95 94.1 
 
1,083 99.4 
 
124 97.6 
 
54 96.4 
 
1,033 99.1 
SCC NOS/Conventional non keratinizing 218 17.2 
 
38 37.6 
 
332 30.5 
 
38 29.9 
 
14 25.0 
 
219 21.0 
Conventional keratinizing 955 75.6 
 
32 31.7 
 
603 55.3 
 
71 55.9 
 
31 55.4 
 
712 68.3 
Conventional exophytic keratinizing 17 1.3 
 
4 4.0 
 
8 0.7 
 
0 0.0 
 
0 0.0 
 
12 1.2 
Basaloid/Papillary 39 3.1 
 
20 19.8 
 
129 11.8 
 
12 9.4 
 
9 16.1 
 
70 6.7 
Verrucous 8 0.6 
 
0 0.0 
 
1 0.1 
 
0 0.0 
 
0 0.0 
 
4 0.4 
Sarcomatoid 20 1.6 
 
1 1.0 
 
10 0.9 
 
3 2.4 
 
0 0.0 
 
16 1.5 
Undifferentiated Carcinoma 2 0.2 
 
6 5.9 
 
5 0.5 
 
3 2.4 
 
1 1.8 
 
8 0.8 
Adenosquamous carcinoma 5 0.4 
 
0 0.0 
 
2 0.2 
 
0 0.0 
 
1 1.8 
 
1 0.1 
"SCC": Squamous Cell Carcinoma; "SD": Standard Deviation; "NOS": Not Otherwise Specified. 576 
 577 
  578 
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Table 2. HPV-DNA positivity and detected types, and E6*I mRNA, p16INK4a, pRb, p53 and Cyclin D1 results among HPV DNA positive cases, by head and neck cancer site 579 
 580 
  
Oral cavity   Nasopharynx   Oropharynx   Hypopharynx   
Pharynx 
unspecified   Larynx 
 n=1,264   n=101   n=1,090   n=127   n=56   n=1,042 
  n %   n %   n %   n %   n %   n % 
HPV DNA positivity * 93 7.4 
 
9 8.9 
 
273 25.0 
 
5 3.9 
 
12 21.4 
 
61 5.9 
Type of HPV infection † 
Single 81 87.1 
 
9 100.0 
 
269 98.5 
 
5 100 
 
11 91.7 
 
58 95.1 
Multiple ‡ 5 5.4 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
1 1.6 
Undetermined genotype § 7 7.5 
 
0 0.0 
 
3 1.1 
 
0 0.0 
 
1 8.3 
 
2 3.3 
HPV type distribution in single 
infection2 
                 HPV6 0 0.0 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
4 6.6 
HPV11 1 1.1 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
1 1.6 
HPV13|| 2 2.1 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
1 8.3 
 
0 0.0 
HPV16 64 68.8 
 
7 77.8 
 
227 83.2 
 
4 80.0 
 
8 66.7 
 
32 52.6 
HPV18 1 1.1 
 
0 0.0 
 
5 1.8 
 
0 0.0 
 
0 0.0 
 
3 4.9 
HPV19|| 0 0.0 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV26|| 1 1.1 
 
0 0.0 
 
7 2.6 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV30|| 0 0.0 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV31 0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
2 3.3 
HPV33 0 0.0 
 
0 0.0 
 
9 3.4 
 
1 20.0 
 
0 0.0 
 
2 3.3 
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HPV35 2 2.1 
 
1 11.1 
 
6 2.2 
 
0 0.0 
 
1 8.3 
 
1 1.6 
HPV39 1 1.1 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
3 4.9 
HPV45 0 0.0 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
5 8.2 
HPV51 2 2.1 
 
0 0.0 
 
2 0.7 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV52 4 4.3 
 
1 11.1 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV53 1 1.1 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV56 0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
1 1.6 
HPV58 1 1.1 
 
0 0.0 
 
2 0.7 
 
0 0.0 
 
0 0.0 
 
1 1.6 
HPV59 0 0.0 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV66 0 0.0 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV67|| 0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
1 8.3 
 
1 1.6 
HPV68 0 0.0 
 
0 0.0 
 
1 0.4 
 
0 0.0 
 
0 0.0 
 
2 3.3 
HPV69|| 0 0.0 
 
0 0.0 
 
2 0.7 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV90|| 1 1.1 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
 
0 0.0 
HPV types grouped by risk and vaccine†¶ 
                Only high risk types 77 82.8 
 
9 100.0 
 
267 97.8 
 
5 100.0 
 
10 83.3 
 
53 86.9 
Only low risk types 4 4.3 
 
0 0.0 
 
2 0.7 
 
0 0.0 
 
1 8.3 
 
5 8.2 
Types in bivalent vaccine 65 69.9 7 77.8 232 85.0 4 80.0 8 66.7 35 57.4 
Types in quadrivalent vaccine 66 71.0  7 77.8  233 85.3  4 80.0  8 66.7  40 65.6 
Types in ninevalent vaccine 71 76.3  8 88.9  245 89.7  5 100.0  8 66.7  50 82.0 
Contribution of other markers# 
+ / 
tested 
%+  
+ / 
tested 
%+  
+ / 
tested 
%+  
+ / 
tested 
%+  
+ / 
tested 
%+  
+ / 
tested 
%+ 
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E6*I mRNA+ 49/80 61.3  6/9 66.7  235/260 90.4  3/5 60.0  8/9 88.9  32/52 61.5 
p16INK4a+ 44/91 48.4  1/3 33.3  207/267 77.5  3/5 60.0  5/12 41.7  20/61 32.8 
pRb-** 55/93 59.1  2/3 66.7  221/267 82.8  3/5 60.0  8/12 66.7  35/60 58.3 
p53-** 77/91 84.6  3/3 100  244/265 92.1  4/5 80.0  11/12 91.7  40/58 69.0 
Cyclin D1-** 49/93 52.7  2/3 66.7  174/267 65.2  3/5 60.0  9/12 75.0  22/60 36.7 
E6*I mRNA+ OR p16INK4a + 55/93 59.1  6/7 85.7  243/268 90.8  3/5 60.0  9/12 75.0  36/61 59.0 
E6*I mRNA+ AND p16INK4a + 38/78 48.7  1/3 33.3  199/259 76.8  3/5 60.0  4/9 44.4  16/52 30.8 
* Percentage of HPV-DNA positive cases among all cases tested by DEIA (see Methods). 581 
† Percentages among HPV-DNA positive cases. 582 
‡ Multiple infections were: Oral cavity: HPV 6&52 (n=2), HPV 16&52 (n=1), HPV 16&59 (n=1), and HPV 31&52 (n=1); Oropharynx: HPV 16&56 (n=1); Larynx: HPV18&44 (n=1). 583 
§ HPV undetermined denotes cases that were DEIA positive but line probe assay LiPA25 negative.  584 
|| Genotype identified by sequencing. 585 
¶ Multiple infections (n=7) are not included in these groups. Risk groups are defined according to the last IARC classification: we considered as high risk HPV types the types 586 
included in Group 1, Group 2A and Group 2B; other HPV types were classified as low risk HPV types27. 587 
# Percentages among HPV DNA positive cases that were tested for each specific marker or combination of markers. Positivity for each individual marker refers to: detection of E6*I 588 
mRNA, over-expression of p16INK4a and under-expression of pRb, p53, or Cyclin D1.  589 
** Under-expression 590 
  591 
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Table 3. Prevalence of HPV-DNA, HPV types, E6*I mRNA and p16INK4a, and estimates of HPV attributable fractions by head and neck cancer site and key patients’ 592 
characteristics 593 
 
HPV-DNA 
prevalence 
 HPV16  
Any 
HR HPV 
types 
 E6*I mRNA  p16INK4a  HPV attributable fractions (%) 
 
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
&mRNA 
tested 
%  
+/HPV-
DNA &p16 
tested 
%  
HPV-DNA+ AND 
(mRNA+ OR 
p16+) 
 
HPV-DNA+ AND 
mRNA+ AND 
p16+ 
Geographical origin                     
Oral cavity *                    
Europe  46/587 7.8  30/587 5.1  41/587 7.0  18/581 3.1  16/587 2.7  3.8  2.1 
Central-South America  42/488 8.6  33/488 6.8  36/488 7.4  30/482 6.2  27/486 5.6  6.6  5.2 
Africa  2/58 3.4  1/58 1.7  2/58 1.0  0/58 0.0  0/58 0.0  0.0  0.0 
Asia  1/99 1.0  0/99 0.0  1/99 6.5  0/98 0.0  0/99 0.0  0.0  0.0 
Oropharynx *†                    
Europe  183/810 22.6  157/810 19.4  181/810 22.3  157/803 19.6  131/805 16.3  19.9  15.9 
Central-South America  68/158 43.0  51/158 32.3  65/158 41.1  60/153 39.2  58/157 36.9  40.5  35.5 
Asia  21/103 20.4  20/103 19.4  21/103 20.4  18/103 17.5  18/103 17.5  18.5  16.5 
Larynx *                     
Europe  25/505 5.0  17/505 3.4  24/505 4.8  11/504 2.2  7/505 1.4  2.4  1.2 
Central-South America  30/359 8.4  13/359 3.6  26/359 7.2  19/354 5.4  13/359 3.6  6.1  2.8 
Africa  5/73 6.8  2/73 2.7  4/73 5.5  2/71 2.8  0/73 0.0  2.7  0.0 
Asia  1/71 1.4  0/71 0.0  0/71 0.0  0/70 0.0  0/71 0.0  0.0  0.0 
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HPV-DNA 
prevalence 
 HPV16  
Any 
HR HPV 
types 
 E6*I mRNA  p16INK4a  HPV attributable fractions (%) 
 
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
&mRNA 
tested 
%  
+/HPV-
DNA &p16 
tested 
%  
HPV-DNA+ AND 
(mRNA+ OR 
p16+) 
 
HPV-DNA+ AND 
mRNA+ AND 
p16+ 
Gender                     
Oral cavity                     
Male  58/781 7.4  43/781 5.5  50/781 6.4  32/772 4.2  30/781 3.8  4.7  3.2 
Female  35/471 7.4  23/471 4.9  32/471 6.8  17/467 3.6  14/469 3.0  3.8  2.8 
Oropharynx                                       
Male  198/884 22.4  168/884 19.0  194/884 21.9  170/876 19.4  147/880 16.7  19.9  16.2 
Female  72/178 40.4  57/178 32.0  71/178 39.9  65/174 37.4  60/177 33.9  38.4  32.8 
Larynx                                                
Male  47/929 5.1  26/929 2.8  42/929 4.5  23/922 2.5  14/929 1.5  2.8  1.2 
Female  14/109 12.8  6/109 5.5  12/109 11.0  9/107 8.4  6/109 5.5  9.2  4.7 
Year of diagnosis                    
Oral cavity                                         
1990-1994  0/35 0.0  0/35 0.0  0/35 0.0  0/35 0.0  0/35 0.0  0.0  0.0 
1995-1999  5/66 7.6  4/66 6.1  5/66 7.6  3/66 4.5  3/66 4.5  4.5  4.5 
2000-2004  12/152 7.9  9/152 5.9  10/152 6.6  5/149 3.4  5/152 3.3  3.3  3.4 
2005-2009  60/693 8.7  45/693 6.5  56/693 8.1  35/689 5.1  28/691 4.1  5.5  3.6 
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HPV-DNA 
prevalence 
 HPV16  
Any 
HR HPV 
types 
 E6*I mRNA  p16INK4a  HPV attributable fractions (%) 
 
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
&mRNA 
tested 
%  
+/HPV-
DNA &p16 
tested 
%  
HPV-DNA+ AND 
(mRNA+ OR 
p16+) 
 
HPV-DNA+ AND 
mRNA+ AND 
p16+ 
2010-2012  16/318 5.0  8/318 2.5  11/318 3.5  6/312 1.9  8/318 2.5  2.8  1.6 
Oropharynx                                        
1990-1994  9/83 10.8  5/83 6.0  8/83 9.6  6/81 7.4  4/83 4.8  7.2  4.9 
1995-1999  13/129 10.1  11/129 8.5  13/129 10.1  13/129 10.1  12/129 9.3  10.1  9.3 
2000-2004  48/226 21.2  42/226 18.6  48/226 21.2  39/224 17.4  39/224 17.4  18.7  16.1 
2005-2009  136/455 29.9  118/455 25.9  132/455 29.0  114/447 25.5  96/452 21.2  26.1  20.6 
2010-2012  67/197 34.0  52/197 26.4  67/197 34.0  63/196 32.1  56/196 28.6  32.7  28.1 
Larynx                                                   
1990-1994  0/18 0.0  0/18 0.0  0/18 0.0  0/18 0.0  0/18 0.0  0.0  0.0 
1995-1999  0/26 0.0  0/26 0.0  0/26 0.0  0/26 0.0  0/26 0.0  0.0  0.0 
2000-2004  9/156 5.8  4/156 2.6  7/156 4.5  4/153 2.6  4/156 2.6  3.2  2.0 
2005-2009  36/542 6.6  20/542 3.7  33/542 6.1  19/539 3.5  11/542 2.0  4.1  1.5 
2010-2012  16/300 5.3  8/300 2.7  14/300 4.7  9/297 3.0  5/300 1.7  3.0  1.7 
Age at diagnosis                     
Oral cavity                    
≤53  27/336 8.0  16/336 4.8  23/336 6.8  14/332 4.2  15/335 4.5  5.1  3.6 
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HPV-DNA 
prevalence 
 HPV16  
Any 
HR HPV 
types 
 E6*I mRNA  p16INK4a  HPV attributable fractions (%) 
 
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
tested 
%  
+/HPV-
DNA 
&mRNA 
tested 
%  
+/HPV-
DNA &p16 
tested 
%  
HPV-DNA+ AND 
(mRNA+ OR 
p16+) 
 
HPV-DNA+ AND 
mRNA+ AND 
p16+ 
54-61  16/256 6.3  13/256 5.1  14/256 5.5  10/252 4.0  9/255 3.5  4.3  3.2 
62-70  21/273 7.7  18/273 6.6  21/273 7.7  10/273 3.7  10/273 3.7  4.4  2.9 
≥71  25/313 8.0  15/313 4.8  20/313 6.4  12/308 3.9  8/313 2.6  3.8  2.6 
Oropharynx                                         
≤53  93/273 34.1  80/273 29.3  92/273 33.7  84/270 31.1  74/272 27.2  32.4  25.9 
54-61  81/293 27.6  70/293 23.9  79/293 27.0  72/290 24.8  63/292 21.6  25.0  21.4 
62-70  55/285 19.3  40/285 14.0  54/285 18.9  47/282 16.7  43/284 15.1  17.3  14.5 
≥71  41/205 20.0  36/205 17.6  40/205 19.5  32/203 15.8  27/203 13.3  16.2  12.9 
Larynx                                                   
≤53  24/210 11.4  13/210 6.2  22/210 10.5  13/207 6.3  8/210 3.8  7.1  2.9 
54-61  15/293 5.1  7/293 2.4  13/293 4.4  8/291 2.8  7/293 2.4  3.1  2.1 
62-70  10/287 3.5  2/287 2.4  10/287 3.5  4/287 1.4  3/287 1.1  1.7  0.7 
≥71  10/214 4.7  5/214 2.3  9/214 4.2  7/212 3.3  2/214 0.9  3.3  0.9 
* Excludes North America because of low number of cases tested (<45). 594 
† Excludes Africa because of low number of cases tested (<45). 595 
"HR": High Risk types; Risk groups are defined according to the last IARC classification: we considered as high risk HPV types those included in Group 1, Group 2A and Group 2B; other HPV types were 596 
classified as low risk HPV types 27; Any HPV16 or any HPV HR types found in either single or multiple infections are included in the corresponding columns. 597 
 598 
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Figures legends 600 
Figure 1. Samples disposition and testing for HPV-related biomarkers. (*) Excludes samples that 601 
were too hemorrhagic or necrotic for appropriate assessment or processing. (†) Includes 602 
both cases that were HPV-DNA positive and cases that were HPV-DNA negative but 603 
tubulin positive; (‡) For E6*I mRNA, includes cases with available material that tested 604 
positive for an HPV type for which the type-specific mRNA detection assay was available; 605 
For immunohistochemistry assays, includes cases with available material. “H&E”: 606 
Haematoxylin and Eosin; “Uns.”: Unspecified. 607 
 608 
Figure 2. HPV attributable fractions in head and neck cancers according to positivity and/or 609 
overexpression of selected biomarkers of HPV induced carcinogenesis. “n”: Number of 610 
positive cases; “N”: Number of tested cases for the specified markers; “CI”: 95% 611 
confidence interval; “Uns.”: Unspecified .  612 
 613 
Figure 3. HPV attributable fractions in head and neck cancers by subregión according to 614 
positivity and/or overexpression of selected biomarkers of HPV induced carcinogenesis. (*) 615 
Excludes North America and Eastern-Southern Asia because of low number of cases 616 
tested (<45). (†) Excludes Western Africa, Northern America, Central-Southern Asia, and 617 
South-Eastern Asia because of low number of cases tested (<45). (‡) Excludes North 618 
America, Central-Southern Asia, Eastern Asia , and Western Asia because of low number 619 
of  cases tested (<45). “AF”: attributable fraction. 620 
 621 
  622 
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